These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24529523)

  • 1. First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease.
    Hölscher C
    Alzheimers Dement; 2014 Feb; 10(1 Suppl):S33-7. PubMed ID: 24529523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia.
    Claxton A; Baker LD; Hanson A; Trittschuh EH; Cholerton B; Morgan A; Callaghan M; Arbuckle M; Behl C; Craft S
    J Alzheimers Dis; 2015; 44(3):897-906. PubMed ID: 25374101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal insulin improves cognition and modulates beta-amyloid in early AD.
    Reger MA; Watson GS; Green PS; Wilkinson CW; Baker LD; Cholerton B; Fishel MA; Plymate SR; Breitner JC; DeGroodt W; Mehta P; Craft S
    Neurology; 2008 Feb; 70(6):440-8. PubMed ID: 17942819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.
    Hölscher C
    Biochem Soc Trans; 2014 Apr; 42(2):593-9. PubMed ID: 24646283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
    Hölscher C
    Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal Insulin for Alzheimer's Disease.
    Hallschmid M
    CNS Drugs; 2021 Jan; 35(1):21-37. PubMed ID: 33515428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments.
    Benedict C; Frey WH; Schiöth HB; Schultes B; Born J; Hallschmid M
    Exp Gerontol; 2011; 46(2-3):112-5. PubMed ID: 20849944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease.
    Zhang C; Chen J; Feng C; Shao X; Liu Q; Zhang Q; Pang Z; Jiang X
    Int J Pharm; 2014 Jan; 461(1-2):192-202. PubMed ID: 24300213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular Vesicle Biomarkers Track Cognitive Changes Following Intranasal Insulin in Alzheimer's Disease.
    Mustapic M; Tran J; Craft S; Kapogiannis D
    J Alzheimers Dis; 2019; 69(2):489-498. PubMed ID: 30958348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease.
    Stein MS; Scherer SC; Ladd KS; Harrison LC
    J Alzheimers Dis; 2011; 26(3):477-84. PubMed ID: 21694461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review.
    Avgerinos KI; Kalaitzidis G; Malli A; Kalaitzoglou D; Myserlis PG; Lioutas VA
    J Neurol; 2018 Jul; 265(7):1497-1510. PubMed ID: 29392460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence.
    Freiherr J; Hallschmid M; Frey WH; Brünner YF; Chapman CD; Hölscher C; Craft S; De Felice FG; Benedict C
    CNS Drugs; 2013 Jul; 27(7):505-14. PubMed ID: 23719722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Insulin Signaling for the Treatment of Alzheimer's Disease.
    Chen Y; Zhang J; Zhang B; Gong CX
    Curr Top Med Chem; 2016; 16(5):485-92. PubMed ID: 26268336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.
    Alagiakrishnan K; Sankaralingam S; Ghosh M; Mereu L; Senior P
    Discov Med; 2013 Dec; 16(90):277-86. PubMed ID: 24333407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of nose-to-brain delivery of basic fibroblast growth factor for improving rat memory impairments induced by co-injection of β-amyloid and ibotenic acid into the bilateral hippocampus.
    Feng C; Zhang C; Shao X; Liu Q; Qian Y; Feng L; Chen J; Zha Y; Zhang Q; Jiang X
    Int J Pharm; 2012 Feb; 423(2):226-34. PubMed ID: 22193058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal insulin in Alzheimer's disease: Food for thought.
    Chapman CD; Schiöth HB; Grillo CA; Benedict C
    Neuropharmacology; 2018 Jul; 136(Pt B):196-201. PubMed ID: 29180222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Intranasal Insulin in Improving Cognition in Mild Cognitive Impairment and Alzheimer Disease: A Systematic Review and Meta-analysis.
    Lu J; Xu Z
    Am J Ther; 2019; 26(6):e756-e762. PubMed ID: 30648990
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition.
    Adler BL; Yarchoan M; Hwang HM; Louneva N; Blair JA; Palm R; Smith MA; Lee HG; Arnold SE; Casadesus G
    Neurobiol Aging; 2014 Apr; 35(4):793-801. PubMed ID: 24239383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial.
    Lin CH; Chen PK; Chang YC; Chuo LJ; Chen YS; Tsai GE; Lane HY
    Biol Psychiatry; 2014 May; 75(9):678-85. PubMed ID: 24074637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.